A research result presented at the American Diabetes Association 79th Scientific Session states that Linagliptin is safe and can be administered in Type 2 Diabetes patients and Cardiorenal Diseases. The study had 6979 enrolled participants out of which 26.8% had a history of heart failure and 58.5% had a history of ischemic heart disease
Linagliptin is safe for patients with type 2 diabetes (T2D) and cardiorenal disease, according to research results presented at the American Diabetes Association 79th Scientific Sessions, held June 7 to 11, 2019 in San Francisco, California.
The CARMELINA study (Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus; ClinicalTrials.gov Identifier: NCT01897532) was a randomized placebo-controlled clinical trial designed to assess the cardiovascular safety of linagliptin in T2D and concomitant cardiorenal disease. The researchers used a negative binomial model to assess the effects of linagliptin compared with placebo for all first and recurrent cardiovascular events as well as any-cause hospitalizations.
Of the 6979 enrolled participants (mean age, 66 years; average estimated glomerular filtration rate, 54.6 mL/min/1.73 m2; median urinary albumin-to-creatinine ratio, 162 mg/g), 26.8% had a history of heart failure and 58.5% had a history of ischemic heart disease. When recurrent events were added, the number of events for analysis increased from 5.3% to 57.5% across cardiovascular/heart failure outcomes and 112.4% for hospitalizations.